Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[An exceptional case of disseminated cystic echinococcosis].

La Revue de medecine interne·2026
Same author

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

Allergy·2026
Same author

Distribution of epithelial endoplasmic reticulum stress-related proteins in adult and pediatric Crohn's disease: Association with inflammation and fibrosis.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2025
Same author

Effectiveness of Aerobic Treadmill Training on Walking Distance in Patients with Multiple Sclerosis with Moderate Disability: A Randomised Controlled Multicentre Trial.

NeuroRehabilitation·2025
Same author

Early diagnosis of hereditary angioedema in children: genetic testing should be prioritized.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2025
Same author

Patients with multiple sclerosis and low disability display cautious rotational behavior during gait initiation.

Clinical biomechanics (Bristol, Avon)·2025
Same journal

[Atypical low back pain].

La Revue de medecine interne·2026
Same journal

[Polycythemia associated chronic haemolysis].

La Revue de medecine interne·2026
Same journal

[Persistent headaches in a 55 year-old man].

La Revue de medecine interne·2026
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

[Bradykinin mediated angioedema].

L Bouillet1, I Boccon-Gibod, C Massot

  • 1Centre de référence sur les angiœdèmes bradykiniques (CREAK), clinique universitaire de médecine interne, BP 217, 38043 Grenoble cedex 09, France. LBouillet@chu-grenoble.fr

La Revue De Medecine Interne
|June 12, 2010
PubMed
Summary
This summary is machine-generated.

Bradykinin angioedema (AE) causes recurrent swelling, distinct from allergic reactions. Treatment focuses on managing attacks and preventing future episodes.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

Related Experiment Videos

Last Updated: Jun 12, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

Area of Science:

  • Immunology
  • Genetics
  • Pharmacology

Context:

  • Bradykinin angioedema (AE) presents as acute, recurrent localized swelling.
  • Episodes are self-limiting (24-72 hours) without sequelae, affecting skin or mucous membranes.
  • Corticosteroids are ineffective for bradykinin AE.

Purpose:

  • To outline the characteristics, causes, and management of bradykinin angioedema.
  • To differentiate bradykinin AE from other forms of angioedema.
  • To highlight diagnostic and therapeutic considerations.

Summary:

  • Bradykinin AE can be secondary to C1 inhibitor deficiency, drug-induced (e.g., ACE inhibitors), or estrogen-dependent (Type III) potentially linked to Factor XII mutations.
  • Prognosis is influenced by laryngeal involvement, a significant cause of mortality without treatment.
  • Acute management involves icatibant or C1 inhibitor concentrate; long-term prophylaxis includes danazol or tranexamic acid.

Impact:

  • Improved understanding of bradykinin AE pathophysiology and classification.
  • Guidance for clinicians on diagnosis and differential diagnosis.
  • Informed therapeutic strategies for acute and chronic management, potentially reducing mortality.